Conditions: Neuroendocrine Tumors
Keywords: Double blind Phase III Disease Clinical trial Octreotide Neuroendocrine tumor Cancer Tumor Midgut
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 85
Healthy volunteers: no

Brief summary:
Placebo-controlled prospective randomized phase III study to investigate the antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of the midgut

Detailed description:

Arms:
arm 1: Octreotide LAR 30 mg intramuscularly every 28 days arm 2: Placebo - Sodium chloride intramuscularly every 28 days

Interventions: intervention 1: Octreotide LAR (Long-acting release) intervention 2: Placebo
Intervention descriptions: intervention 1: 30 mg intramuscularly every 28 days intervention 2: Sodium chloride intramuscularly every 28 days

Protocol document: